Cargando…

Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT

BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Šťastná-Marková, Markéta, Hamšíková, Eva, Hainz, Petr, Hubáček, Petr, Kroutilová, Marie, Kryštofová, Jitka, Ludvíková, Viera, Musil, Jan, Pecherková, Pavla, Saláková, Martina, Šroller, Vojtěch, Vydra, Jan, Němečková, Šárka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625163/
https://www.ncbi.nlm.nih.gov/pubmed/34835157
http://dx.doi.org/10.3390/vaccines9111226
_version_ 1784606352429023232
author Šťastná-Marková, Markéta
Hamšíková, Eva
Hainz, Petr
Hubáček, Petr
Kroutilová, Marie
Kryštofová, Jitka
Ludvíková, Viera
Musil, Jan
Pecherková, Pavla
Saláková, Martina
Šroller, Vojtěch
Vydra, Jan
Němečková, Šárka
author_facet Šťastná-Marková, Markéta
Hamšíková, Eva
Hainz, Petr
Hubáček, Petr
Kroutilová, Marie
Kryštofová, Jitka
Ludvíková, Viera
Musil, Jan
Pecherková, Pavla
Saláková, Martina
Šroller, Vojtěch
Vydra, Jan
Němečková, Šárka
author_sort Šťastná-Marková, Markéta
collection PubMed
description BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st–2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with “non-reactive” anti-BKPyV IgG levels and with low clinical risk (LCR) (p = 0.0009). The predictive value of pretransplant BKPyV-specific IgG was confirmed by determination of genotypes of the shed virus. A positive predictive value was also found for pretransplant T-cell immunity to the BKPyV antigen VP1 because the magnitude of IFN-γ T-cell response inversely correlated with posttransplant DNAuria and with HC. Our novel data suggest that specific T-cells control BKPyV latency before HSCT, and in this way may influence BKPyV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of HSCT recipients at high risk of BKPyV disease.
format Online
Article
Text
id pubmed-8625163
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86251632021-11-27 Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT Šťastná-Marková, Markéta Hamšíková, Eva Hainz, Petr Hubáček, Petr Kroutilová, Marie Kryštofová, Jitka Ludvíková, Viera Musil, Jan Pecherková, Pavla Saláková, Martina Šroller, Vojtěch Vydra, Jan Němečková, Šárka Vaccines (Basel) Article BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st–2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with “non-reactive” anti-BKPyV IgG levels and with low clinical risk (LCR) (p = 0.0009). The predictive value of pretransplant BKPyV-specific IgG was confirmed by determination of genotypes of the shed virus. A positive predictive value was also found for pretransplant T-cell immunity to the BKPyV antigen VP1 because the magnitude of IFN-γ T-cell response inversely correlated with posttransplant DNAuria and with HC. Our novel data suggest that specific T-cells control BKPyV latency before HSCT, and in this way may influence BKPyV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of HSCT recipients at high risk of BKPyV disease. MDPI 2021-10-22 /pmc/articles/PMC8625163/ /pubmed/34835157 http://dx.doi.org/10.3390/vaccines9111226 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Šťastná-Marková, Markéta
Hamšíková, Eva
Hainz, Petr
Hubáček, Petr
Kroutilová, Marie
Kryštofová, Jitka
Ludvíková, Viera
Musil, Jan
Pecherková, Pavla
Saláková, Martina
Šroller, Vojtěch
Vydra, Jan
Němečková, Šárka
Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT
title Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT
title_full Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT
title_fullStr Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT
title_full_unstemmed Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT
title_short Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT
title_sort pretransplant bk virus-specific t-cell-mediated immunity and serotype specific antibodies may have utility in identifying patients at risk of bk virus-associated haemorrhagic cystitis after allogeneic hsct
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625163/
https://www.ncbi.nlm.nih.gov/pubmed/34835157
http://dx.doi.org/10.3390/vaccines9111226
work_keys_str_mv AT stastnamarkovamarketa pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT hamsikovaeva pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT hainzpetr pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT hubacekpetr pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT kroutilovamarie pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT krystofovajitka pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT ludvikovaviera pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT musiljan pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT pecherkovapavla pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT salakovamartina pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT srollervojtech pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT vydrajan pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct
AT nemeckovasarka pretransplantbkvirusspecifictcellmediatedimmunityandserotypespecificantibodiesmayhaveutilityinidentifyingpatientsatriskofbkvirusassociatedhaemorrhagiccystitisafterallogeneichsct